What question did this study set out to answer?

This research aims to evaluate the impact of shortened venetoclax exposure on treatment tolerability and overall survival in older patients with acute myeloid leukaemia.

August 1, 2026European Journal Of HaematologyOpen Access

Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia

View Full Paper

Ask AI

Bookmark

This research aims to evaluate the impact of shortened venetoclax exposure on treatment tolerability and overall survival in older patients with acute myeloid leukaemia.
Retrospective analysis of 61 elderly acute myeloid leukaemia patients treated with venetoclax and hypomethylating agents.
Patients received venetoclax for varying durations: 7 days, 14 days, or more than 14 days per cycle.
Analysis included evaluation of response rates, overall survival, and toxicity events.
Best overall response rate was 76% with no significant differences between treatment schedules (p = 0.38).
Median overall survival was longer for the 7d group (28.4 months) compared to 14d (11.4 months) and > 14d (6.7 months), with p = 0.23.
The 7d schedule showed lower rates of grade 4 cytopenias and fewer infections compared to longer schedules, while associated with improved overall survival (HR 0.33, p = 0.03).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective analysis demonstrates improved tolerability of short venetoclax exposure in older AML patients, implying potential for better treatment plans.

Cite This Study

Steiner et al. (2026) studied this question.

synapsesocial.com/papers/6a6d9874e258b358b3c6be70 https://doi.org/10.1111/ejh.70279

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis demonstrates improved tolerability of short venetoclax exposure in older AML patients, implying potential for better treatment plans.

Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia

Key Points

Discussion

Implication

Cite This Study

Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider